In
HIV and ID Observations, Dr. Paul Sax discusses the approval of a new fluoroquinolone.
The FDA recently approved a new fluoroquinolone, delafloxacin, to treat skin and soft-tissue infections. In the latest HIV and ID Observations, Dr. Paul Sax wonders why we need another treatment for skin infections, especially with the toxicity profile of quinolones.
Want to see more from NEJM Journal Watch? Register here.